Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Liabilities (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Total Liabilities data on record, last reported at $52.2 million in Q3 2025.

  • For Q3 2025, Total Liabilities fell 14.78% year-over-year to $52.2 million; the TTM value through Sep 2025 reached $52.2 million, down 14.78%, while the annual FY2024 figure was $42.5 million, 38.16% down from the prior year.
  • Total Liabilities reached $52.2 million in Q3 2025 per STOK's latest filing, up from $49.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $77.1 million in Q2 2022 and bottomed at $42.5 million in Q4 2024.
  • Average Total Liabilities over 4 years is $64.0 million, with a median of $66.7 million recorded in 2023.
  • The widest YoY moves for Total Liabilities: up 2.51% in 2024, down 38.16% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $71.2 million in 2022, then decreased by 3.43% to $68.8 million in 2023, then plummeted by 38.16% to $42.5 million in 2024, then rose by 22.63% to $52.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $52.2 million in Q3 2025, $49.6 million in Q2 2025, and $56.8 million in Q1 2025.